Publications by authors named "Dmytro Fedkov"
Introduction: Recently, diet has received considerable attention as an important factor in inflammatory arthritis. The objective of this study was to evaluate disease activity and fatigue in patients with rheumatoid arthritis and spondyloarthritis (including psoriatic arthritis) depending on their dietary preferences.
Material And Methods: We retrospectively evaluated data of 774 patients collected by the Mida Rheuma App from January 2022 to December 2022.
Background: Mobile applications (apps) are a resource for information on lifestyle and nutrition which are associated to improved outcomes in inflammatory arthritis.
Objective: The aim of this study was to explore whether targeted lifestyle counselling via an app improves disease activity in arthritis patients.
Methods: Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) were randomized to 12 weeks of lifestyle counselling via an app (Mida, Midaia GmbH, Germany) pertaining to a healthy Mediterranean Diet, physical activity, and mental health.
EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment.
View Article and Find Full Text PDFThe lack of valid biomarkers in patients with spondyloarthritis (SpA) requires searching for additional options to increase sacroiliac joint (SIJ) evaluation effectiveness. We assessed the serum levels of bone turnover markers and their relationships with active and chronic changes in SIJs using magnetic resonance imaging (MRI), indices, and laboratory parameters of disease activity in SpA patients. 102 patients with SpA and 15 healthy subjects were included.
View Article and Find Full Text PDFErdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis associated with BRAFV600E mutations in more than 50% of cases and presenting with 95% with skeletal lesions. However, cutaneous, pulmonary, large vessels and central nervous system involvement can also occur. We report a case of a 25-year-old woman who was admitted in 2018 for exploration of diffuse bone pain and rashes on the face.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess fenebrutinib, a selective BTK inhibitor, for treating patients with active rheumatoid arthritis (RA) who didn't respond well to methotrexate.
- In the first cohort, patients taking higher doses of fenebrutinib showed better improvement in RA symptoms compared to placebo and were similar in effectiveness to adalimumab, while the second cohort also indicated positive outcomes for fenebrutinib.
- The results suggest fenebrutinib is an effective and safe treatment option for RA, potentially targeting both B and myeloid cells, making it a promising new approach in managing the condition.